Key facts
- Kondree’s last known valuation is $3.7M (Feb 2025).
- It has raised $2.4M; the latest was Early Stage VC ($1.9M) in Jan 2026.
- Notable investors include Bpifrance, Banque Populaire du Sud, Business & Innovation Center, Crédit Agricole Mutuel du Languedoc, SATT AxLR.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Kondree
- ·The full record, as it builds
Funding rounds
No funding rounds for Kondree are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kondree
Operator of a biotech-medtech company intended to transform academic research on oxidative stress into personalized antioxidant therapies that improve the quality of life for patients with Facioscapulohumeral Muscular Dystrophy and related conditions. The company offers a scientifically validated, bioanalysis-driven approach to tailor antioxidant supplementation based on individual blood profiles, enabling customers to safely manage oxidative stress, improve muscle strength, reduce frailty and benefit from precision medicine solutions that bridge cutting-edge research with real-world patient care.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2021
- Employees
- 5
- Website
- kondree.com/
- Ownership
- Privately Held (backing)
Kondree doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kondree shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kondree in its N-PORT filings yet. We sweep new filings monthly.